Beijing Bohui Innovation Biotechnology Group Co., Ltd. researches, develops, produces, sells, and services in-vitro diagnostic products in China and internationally. Its offerings include human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; human serum albumin; human prothrombin complex and human coagulation factor VIII; and rabies vaccine. The company also provides molecular diagnostics platforms such as the Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer (BHQ-III) and the GenPlex BHF-VI Nucleic Acid Chip Analyzer, along with trace element analyzers, fluorescence immunoassay analyzers, quantum dot analyzers, and detection kits for respiratory, intestinal, and reproductive infections, trace element testing, and allergen testing. In addition, it offers mass spectrometers, plate readers, standardized ion sources, and flash, process, and preparative purification systems. Formerly Beijing Bohui Innovation Biotechnology Co., Ltd., it changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021, was founded in 2001, and is headquartered in Beijing, China.